Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) → 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial.
Heikki Joensuu(Orion Corporation (Finland)), for The Finnish Breast Cancer Group(Helsinki University Hospital), Arja Jukkola‐Vuorinen(University of Oulu), James D. Ahlgren(Helsinki University Hospital), Mila Tanner(Helsinki University Hospital), Riikka Huovinen(Turku University Hospital), Henrik Lindman(Uppsala University), R. Asola(Satakunta Central Hospital), Petri Bono(Helsinki University Hospital), Pirkko Kellokumpu‐Lehtinen(Tampere University Hospital), R. Kokko
Cited by 8
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k